167. A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients with staphylococcus Aureus Bacteremia Receiving Standard-of-care Antibiotics

BACKGROUND: New treatment approaches for complicated Staphylococcus aureus bacteremia (SAB) are needed. DSTA4637S is a THIOMAB(TM) antibody-antibiotic conjugate consisting of an engineered human IgG1 monoclonal antibody that binds to wall teichoic acid at the surface of S. aureus, a protease-cleavab...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jeremy, Lewin-Koh, Nicholas, Chu, Tom, Rymut, Sharon M, Berhanu, Aklile, Carrasco-Triguero, Montserrat, Rosenberger, Carrie C, Hazenbos, Wouter L, Miller, Loren G, Fowler, Vance G, Miro, Jose M, Couch, Jessica A, Peck, Melicent C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778177/
http://dx.doi.org/10.1093/ofid/ofaa439.477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778177/
http://dx.doi.org/10.1093/ofid/ofaa439.477

Ejemplares similares